Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetic retinopathy 2 endocrinologydiseases
hyperglycemia 5 endocrinologydiseases
simvastatin 3 endocrinologydiseasesdrugs
Insulin 2 endocrinologydiseasesdrugs
diabetes mellitus 1 endocrinologydiseases
diabetic foot 1 endocrinologydiseases
sitagliptin 4 endocrinologydiseasesdrugs
acarbose 1 endocrinologydiseasesdrugs
metformin 23 endocrinologydiseasesdrugs
pioglitazone 3 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 32822 AmlodipineVEGF/Akt/eNOSDiabetesSun et al. [[158]] Biomed Res Int. 2016 AliskirenSDFDiabetesChang et al. [[159]] PLoS One. 2015[227] Insulin and Glargine–DiabetesOikonomou et al. [[160]] Cardiovasc Diabetol. 2014 Ginkgo Biloba extractSODDiabetesZhao
Insulin 33170 betaDiabetesHibbert et al. [[163]] Diabetes. 2014 SimvastatineNOSRetinopathyZhang et al. [[164]] Exp Eye Res. 2012 Insulin DiabetesDong et al. [[165]] Microvasc Res. 2011 SitagliptinSDFDiabetesFadini et al. [[166]] Diabetes
acarbose 34064 potential in DM mice via Akt/eNOS pathway [[170]]. In line with this observation for vitamin D and acarbose , crocetin enhances NO bioavailability via PI3K/Akt-eNOS and ROS pathway [[171]].Several other drugs
metformin 2217 signaling mystery underlying in the diseased and normal condition.ConclusionFinally, we conclude on eNOS- metformin -HSp90 signaling and its remedial effect for controlling the EPC to improve the diabetic condition for
metformin 17038 low. Interestingly, it has been shown that via multifactorial intervention of well-known drugs like metformin , statins, ACE blockers the number and function of circulating EPC can be improved in diabetic patients
metformin 31555 and experimental drugs that increase EPC in diabetes conditionTreatment of diabetes by standard drug metformin , thiazolidinediones, DPP4, insulin, stain and ACE inhibitor may increase number and improve the function
metformin 31977 vildagliptin, sitagliptin and aliskiren play a therapeutic role via cytokine SDF. On the other hand, amlodipine metformin , and simvastatin play a therapeutic role via eNOS while Pioglitazone plays a therapeutic role via ICAM
metformin 34309 number and function of EPC in diabetes cases. Few have been listed in Table 3 such as vildagliptin, metformin , amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin, sitagliptin, adiponectin, pioglitazone.
metformin 34588 level of EPC via increasing cytokine SDF [[172]] for the release of EPC. The other well known drug metformin works via AMPK/eNOS pathway while amlodipine works via VEGF/Akt/eNOS pathway. Simvastatin also works
metformin 35229 neuraminidase, GST along with the protein mapping of eNOS for its binding site. All the target protein of metformin obtained via PharmMapper analysis, and its docking value with metformin have been shown in Table 4
metformin 35301 site. All the target protein of metformin obtained via PharmMapper analysis, and its docking value with metformin have been shown in Table 4 and few have been shown in Fig. 3. Table 5 also lists that these proteins
metformin 35973 357, 360, 361, 362) and polymorphism found in diabetes and uncoupling siteTable 4Predicted target of metformin via PharmMapper and its docking value with different targetsMetforminS. no.Protein nameEST. free energy
metformin 38258 beta secretase and Fructose 1,6 bisphosphatase, which explains the reason for the therapeutic value of metformin . The uncoupled eNOS leads to decrease NO availability and hence low level of MMP9, SDF-1 and immobilized
metformin 38726 person.Fig. 4Signalling pathway in normal and hyperglycemia patients. Diabetes can be corrected by metformin . The major target of metformin is highlighted in red i.e. Uncoupled eNOS, HSp90, GST, CDK2, neuraminidaseThe
metformin 38757 pathway in normal and hyperglycemia patients. Diabetes can be corrected by metformin. The major target of metformin is highlighted in red i.e. Uncoupled eNOS, HSp90, GST, CDK2, neuraminidaseThe above signaling pathway
metformin 38903 eNOS, HSp90, GST, CDK2, neuraminidaseThe above signaling pathway explains the therapeutic value of metformin in mobilizing EPC in diabetes via eNOS-NO-MMP9-cytokine pathway to the damage site for therapy of damaged
metformin 39072 pathway to the damage site for therapy of damaged organ. Recently, reports also have demonstrated that metformin inhibits EPC migration by decreasing MMP 2 and 9 via MAPK/mTOR/autophagy pathway. Till the date, only
metformin 39249 MAPK/mTOR/autophagy pathway. Till the date, only one manuscript in the Pubmed demonstrates the negative effect of metformin in EPC migration while an uncountable number of publication report the positive role of metformin in
metformin 39347 of metformin in EPC migration while an uncountable number of publication report the positive role of metformin in diabetes and clinically metformin is still used for Diabetic patients. Hence in this regard, the
metformin 39384 uncountable number of publication report the positive role of metformin in diabetes and clinically metformin is still used for Diabetic patients. Hence in this regard, the role of metformin is slightly debatable
metformin 39465 diabetes and clinically metformin is still used for Diabetic patients. Hence in this regard, the role of metformin is slightly debatable regarding EPC migration and needs to be validated and confirmed in the future
metformin 39672 future through enough experimental results. Due to scarcity of enough publication, the negative role of metformin needs to be validated in future and due to presence of enough publication for the positive role of metformin
metformin 39781 needs to be validated in future and due to presence of enough publication for the positive role of metformin in diabetes and our own docking study for eNOS-Metformin, we advocate for the positive role of metformin
metformin 39886 metformin in diabetes and our own docking study for eNOS-Metformin, we advocate for the positive role of metformin in diabetes.The HSp90 and eNOS forms complex in normal condition and in hyperglycemia, the complex disrupts.
metformin 40644 and experimental drugs.DM treatment improves the mobilization of EPCDM treatment via vildagliptin, metformin , amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin, sitagliptin, adiponectin, pioglitazone,
metformin 41954 ischemia, diabetic retinopathy and diabetic kidney failure. Our results demonstrate that commonly used drug metformin can convert the dysfunctional EPC to functional EPC via targeting the previously identified targets
pioglitazone 30742 mitochondrial biogenesis by diminished production of mitochondrial ROS and H2O2 levels [[151]]. Also pioglitazone —drug prescribed for patients with type-2 diabetes [[152]], cardio-protective drug puerarin [[153]]
pioglitazone 34415 metformin, amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin, sitagliptin, adiponectin, pioglitazone . The drug vildagliptin, aliskiren, sitagliptin increases the level of EPC via increasing cytokine SDF
pioglitazone 40750 metformin, amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin, sitagliptin, adiponectin, pioglitazone , stain, insulin, ACE inhibitor improves the mobilization of EPC from the bone marrow by release of cytokine
simvastatin 31992 and aliskiren play a therapeutic role via cytokine SDF. On the other hand, amlodipine metformin, and simvastatin play a therapeutic role via eNOS while Pioglitazone plays a therapeutic role via ICAM and VCAM. Certain
simvastatin 34376 in Table 3 such as vildagliptin, metformin, amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin , sitagliptin, adiponectin, pioglitazone. The drug vildagliptin, aliskiren, sitagliptin increases the
simvastatin 40711 EPCDM treatment via vildagliptin, metformin, amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin , sitagliptin, adiponectin, pioglitazone, stain, insulin, ACE inhibitor improves the mobilization of
sitagliptin 31879 inflammation, oxidative stress, insulin resistance and NO bioavailability. Table 3 shows that vildagliptin, sitagliptin and aliskiren play a therapeutic role via cytokine SDF. On the other hand, amlodipine metformin, and
sitagliptin 34389 such as vildagliptin, metformin, amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin, sitagliptin , adiponectin, pioglitazone. The drug vildagliptin, aliskiren, sitagliptin increases the level of EPC
sitagliptin 34463 glargine, cathepsin, simvastatin, sitagliptin, adiponectin, pioglitazone. The drug vildagliptin, aliskiren, sitagliptin increases the level of EPC via increasing cytokine SDF [[172]] for the release of EPC. The other well
sitagliptin 40724 treatment via vildagliptin, metformin, amlodipine, aliskiren, insulin and glargine, cathepsin, simvastatin, sitagliptin , adiponectin, pioglitazone, stain, insulin, ACE inhibitor improves the mobilization of EPC from the
Select Disease Character Offset Disease Term Instance
diabetes mellitus 16234 patients.Impact of EPC circulation and function on clinical parameter and prognosis of DM patientsThe burden of diabetes mellitus is associated with other cardiovascular complications in the body which arises due to low number and
diabetic foot 37352 polymorphismAngiogenesisGonzalez et al. [[177]] Int J Ophthalmol. 2017Lai et al. [[178]] Sci Rep. 2017SDFGeneticCytokine in diabetic foot ulcerGene. 2015NeuraminidaseNovel genePositive regulation for insulin signallingDridi et al. [[179]]
diabetic retinopathy 17731 patients.Pathogenesis of diabetes induced by impaired EPC functionImpaired EPC in diabetic patients leads to diabetic retinopathy , impaired neovascularization and several other complications in DM patients.Circulating number of EPCs
diabetic retinopathy 41856 repair system in diabetes and diabetes-related diseases like cardiovascular disease, hind limb ischemia, diabetic retinopathy and diabetic kidney failure. Our results demonstrate that commonly used drug metformin can convert the
hyperglycemia 13980 terms of decreased proliferation, adhesion and vasculogenesis in DM patients. Additionally, in vitro hyperglycemia or a diabetic intrauterine environment has shown diminished EPC colony formation suggesting that reduced
hyperglycemia 16671 biomarker of global complication burden in diabetic. The damage caused to the body after prolonged hyperglycemia is retinopathy, limb ischemia, neuropathy and other cardio and microvascular complication. The higher
hyperglycemia 26115 The different sources of ROS and means of antioxidant generation contribute to the total ROS level in hyperglycemia condition.Telomere shortening in EPCTelomere erosion is a key factor in endothelial cell senescence.
hyperglycemia 38673 functional EPC for repairing the damage caused in normal person.Fig. 4Signalling pathway in normal and hyperglycemia patients. Diabetes can be corrected by metformin. The major target of metformin is highlighted in red
hyperglycemia 39968 positive role of metformin in diabetes.The HSp90 and eNOS forms complex in normal condition and in hyperglycemia , the complex disrupts. Hence, targeting Hsp90 and eNOS can be a good therapeutic site for treating diabetes.

You must be authorized to submit a review.